Showing 5871-5880 of 9662 results for "".
Business Advisor: Protect Your Practice With Online Reputation Management Strategies
https://practicaldermatology.com/topics/general-topics/business-advisor-protect-your-practice-with-online-reputation-management-strategies/21943/Online communication has affected how patients view physicians and practices. Learn how to know who is saying what about you on the Internet and what to do about itClinical Focus: Psoriasis: New Data on Comorbidities Associated with Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-data-on-comorbidities-associated-with-psoriasis/21979/With data mounting, it is essential that dermatologists monitor all patients who may be at risk for comorbidities and provide referrals when indicated.Natural Ingredients and Their Applications in Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/natural-ingredients-and-their-applications-in-dermatology/22022/Understanding the role of natural ingredients in therapeutic regimens may help physicians to harness these agents for maximum effect.Business Advisor: Mapping Out a Price/Benefit Value Strategy for Your Practice
https://practicaldermatology.com/topics/general-topics/business-advisor-mapping-out-a-pricebenefit-value-strategy-for-your-practice/22043/Using a Price/Benefit map is a good way for practices to set prices and plan to adapt to changing markets.Expanding the Field: A New Botulinum Neurotoxin A Enters The US Arena
https://practicaldermatology.com/topics/general-topics/PD0609_07-php/22816/A cosmetic dermatologist with experience using Dysport describes how clinicians may approach the new agent in practice.Is Bone Mineral Density Testing Indicated with Long-Term IM Triamcinolone Acetonide Therapy?
https://practicaldermatology.com/topics/general-topics/PD1208_05-php/22603/Prospective data are lacking, but early findings suggest little if any risk of density-loss among patients on long-term therapy.Malassezia Sensitization in Head and Neck Atopic Dermatitis: A Meta-Analysis of Prevalence and Diagnostic Markers
https://practicaldermatology.com/topics/atopic-dermatitis/malassezia-sensitization-in-head-and-neck-atopic-dermatitis-a-meta-analysis-of-prevalence-and-diagnostic-markers/57253/In the 2024 study by See Tow and Yew entitled, “Malassezia specific IgE in head and neck dermatitis of eczema: A systematic review & meta-analysis,” the authors found no statistically significant differences in prevalence of dominant Malassezia species but concluded that Malassezia-specific IgEPrecision Medicine for AD
https://practicaldermatology.com/columns/atopic-dermatitis-essentials/precision-medicine-for-ad/54826/A Q & A with Derek MaetzoldCutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuThe ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.